{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:42:03Z","timestamp":1793263323731,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128246","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:42:50Z","timestamp":1768750970000},"page":"128246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Assessing the potential impact of the 20-valent (PCV20) and an adult 21-valent (aPCV21) pneumococcal conjugate vaccine on invasive pneumococcal disease in England"],"prefix":"10.1016","volume":"75","author":[{"given":"Aryan","family":"Nikhab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Wasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariyo","family":"Abdullahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"D'Aeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyi","family":"Eletu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Litt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez N.","family":"Ladhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2026.128246_bb0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128246_bb0010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1473-3099(24)00665-0","article-title":"Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis","volume":"25","author":"Bennett","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128246_bb0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.vaccine.2013.05.005","article-title":"Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects","volume":"32","author":"Davis","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128246_bb0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128246_bb0025","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128246_bb0030","author":"UK Health Security Agency"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128246_bb0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128246_bb0040","author":"UK Health Security Agency"},{"key":"10.1016\/j.vaccine.2026.128246_bb0045","author":"UK Health Security Agency"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128246_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002845","article-title":"Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: a modelling study","volume":"16","author":"Choi","year":"2019","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128246_bb0055","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1473-3099(17)30654-0","article-title":"Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial","volume":"18","author":"Goldblatt","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128246_bb0060","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S1473-3099(20)30492-8","article-title":"Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK","volume":"21","author":"Ladhani","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128246_bb0065","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(23)00706-5","article-title":"Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study","volume":"24","author":"Bertran","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128246_bb0070","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S2352-4642(24)00193-7","article-title":"Characteristics of children with invasive pneumococcal disease eligible for the 1+1 compared with the 2+1 PCV13 infant immunisation schedule in England: a prospective national observational surveillance study","volume":"8","author":"Abdullahi","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128246_bb0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial","volume":"23","author":"Platt","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128246_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101102","article-title":"Whole-genome sequencing, strain composition, and predicted antimicrobial resistance of Streptococcus pneumoniae causing invasive disease in England in 2017-20: a prospective national surveillance study","volume":"6","author":"D\u2019Aeth","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128246_bb0085","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.2477","article-title":"Whole genome sequencing of Streptococcus pneumoniae: development, evaluation and verification of targets for serogroup and serotype prediction using an automated pipeline","volume":"4","author":"Kapatai","year":"2016","journal-title":"PeerJ"},{"issue":"37","key":"10.1016\/j.vaccine.2026.128246_bb0095","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >\/=65 years: recommendations of the advisory committee on immunization practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"46","key":"10.1016\/j.vaccine.2026.128246_bb0100","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >\/=65 years: updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"36","key":"10.1016\/j.vaccine.2026.128246_bb0105","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","article-title":"Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the advisory committee on immunization practices - United States","volume":"73","author":"Kobayashi","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep 2024"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128246_bb0110","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2213-2600(17)30110-8","article-title":"Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study","volume":"5","author":"Savulescu","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.128246_bb0115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","article-title":"Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales","volume":"6","author":"Djennad","year":"2018","journal-title":"EClinicalMedicine"},{"issue":"35","key":"10.1016\/j.vaccine.2026.128246_bb0120","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","article-title":"Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128246_bb0125","unstructured":"Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation - minutes. 2024. https:\/\/www.gov.uk\/government\/groups\/joint-committee-on-vaccination-and-immunisation [accessed 03\/04\/2025]."},{"issue":"6","key":"10.1016\/j.vaccine.2026.128246_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2025.100726","article-title":"Pneumococcal vaccination for new residents entering older adult care homes in England: national observational surveillance study","volume":"6","author":"Abdullahi","year":"2025","journal-title":"Lancet Healthy Longev"},{"issue":"34","key":"10.1016\/j.vaccine.2026.128246_bb0135","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1016\/j.vaccine.2014.03.017","article-title":"Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England","volume":"32","author":"van Hoek","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128246_bb0140","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/infdis\/jiae453","article-title":"Increased proportions of invasive pneumococcal disease cases among adults experiencing homelessness sets the stage for new serotype 4 capsular-switch recombinants","volume":"231","author":"Beall","year":"2025","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128246_bb0145","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz362","article-title":"Homelessness in adults with invasive pneumococcal disease (IPD) in Calgary, Canada","volume":"6","author":"Lemay","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128246_bb0150","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.vaccine.2021.10.046","article-title":"International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in northern European shipyard outbreaks of invasive pneumococcal disease","volume":"40","author":"Gladstone","year":"2022","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128246_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1473-3099(23)00634-5","article-title":"Is it time to reconsider how higher valency pneumococcal conjugate vaccines are evaluated?","volume":"24","author":"Temple","year":"2024","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:51:07Z","timestamp":1772553067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"alternative-id":["S0264410X26000538"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128246","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the potential impact of the 20-valent (PCV20) and an adult 21-valent (aPCV21) pneumococcal conjugate vaccine on invasive pneumococcal disease in England","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128246"}}